Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine
Background:
Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HIV epidemics in Eastern Europe and Central Asia. In Ukraine—chosen in this study as a representative country—IDU-related risk behaviors cause half of new infections, but few injection drug users (IDUs) receive methadone substitution therapy. Only 10% of eligible individuals receive antiretroviral therapy (ART). The appropriate resource allocation between these programs has not been studied. We estimated the effectiveness and cost-effectiveness of strategies for expanding methadone substitution therapy programs and ART in mixed HIV epidemics, using Ukraine as a case study.
Methods and Findings:
We developed a dynamic compartmental model of the HIV epidemic in a population of non-IDUs, IDUs using opiates, and IDUs on methadone substitution therapy, stratified by HIV status, and populated it with data from the Ukraine. We considered interventions expanding methadone substitution therapy, increasing access to ART, or both. We measured health care costs, quality-adjusted life years (QALYs), HIV prevalence, infections averted, and incremental cost-effectiveness. Without incremental interventions, HIV prevalence reached 67.2% (IDUs) and 0.88% (non-IDUs) after 20 years. Offering methadone substitution therapy to 25% of IDUs reduced prevalence most effectively (to 53.1% IDUs, 0.80% non-IDUs), and was most cost-effective, averting 4,700 infections and adding 76,000 QALYs compared with no intervention at US$530/QALY gained. Expanding both ART (80% coverage of those eligible for ART according to WHO criteria) and methadone substitution therapy (25% coverage) was the next most cost-effective strategy, adding 105,000 QALYs at US$1,120/QALY gained versus the methadone substitution therapy-only strategy and averting 8,300 infections versus no intervention. Expanding only ART (80% coverage) added 38,000 QALYs at US$2,240/QALY gained versus the methadone substitution therapy-only strategy, and averted 4,080 infections versus no intervention. Offering ART to 80% of non-IDUs eligible for treatment by WHO criteria, but only 10% of IDUs, averted only 1,800 infections versus no intervention and was not cost effective.
Conclusions:
Methadone substitution therapy is a highly cost-effective option for the growing mixed HIV epidemic in Ukraine. A strategy that expands both methadone substitution therapy and ART to high levels is the most effective intervention, and is very cost effective by WHO criteria. When expanding ART, access to methadone substitution therapy provides additional benefit in infections averted. Our findings are potentially relevant to other settings with mixed HIV epidemics.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000423
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000423
Souhrn
Background:
Injection drug use (IDU) and heterosexual virus transmission both contribute to the growing mixed HIV epidemics in Eastern Europe and Central Asia. In Ukraine—chosen in this study as a representative country—IDU-related risk behaviors cause half of new infections, but few injection drug users (IDUs) receive methadone substitution therapy. Only 10% of eligible individuals receive antiretroviral therapy (ART). The appropriate resource allocation between these programs has not been studied. We estimated the effectiveness and cost-effectiveness of strategies for expanding methadone substitution therapy programs and ART in mixed HIV epidemics, using Ukraine as a case study.
Methods and Findings:
We developed a dynamic compartmental model of the HIV epidemic in a population of non-IDUs, IDUs using opiates, and IDUs on methadone substitution therapy, stratified by HIV status, and populated it with data from the Ukraine. We considered interventions expanding methadone substitution therapy, increasing access to ART, or both. We measured health care costs, quality-adjusted life years (QALYs), HIV prevalence, infections averted, and incremental cost-effectiveness. Without incremental interventions, HIV prevalence reached 67.2% (IDUs) and 0.88% (non-IDUs) after 20 years. Offering methadone substitution therapy to 25% of IDUs reduced prevalence most effectively (to 53.1% IDUs, 0.80% non-IDUs), and was most cost-effective, averting 4,700 infections and adding 76,000 QALYs compared with no intervention at US$530/QALY gained. Expanding both ART (80% coverage of those eligible for ART according to WHO criteria) and methadone substitution therapy (25% coverage) was the next most cost-effective strategy, adding 105,000 QALYs at US$1,120/QALY gained versus the methadone substitution therapy-only strategy and averting 8,300 infections versus no intervention. Expanding only ART (80% coverage) added 38,000 QALYs at US$2,240/QALY gained versus the methadone substitution therapy-only strategy, and averted 4,080 infections versus no intervention. Offering ART to 80% of non-IDUs eligible for treatment by WHO criteria, but only 10% of IDUs, averted only 1,800 infections versus no intervention and was not cost effective.
Conclusions:
Methadone substitution therapy is a highly cost-effective option for the growing mixed HIV epidemic in Ukraine. A strategy that expands both methadone substitution therapy and ART to high levels is the most effective intervention, and is very cost effective by WHO criteria. When expanding ART, access to methadone substitution therapy provides additional benefit in infections averted. Our findings are potentially relevant to other settings with mixed HIV epidemics.
: Please see later in the article for the Editors' Summary
Zdroje
1. MathersBM
DegenhardtL
PhillipsB
WiessingL
HickmanM
2008 Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372 1733 1745
2. CelentanoDD
BeyrerC
WolfeD
ElovichR
BoltaevA
2008 HIV in Central Asia: Tajikistan, Uzbekistan and Kyrgyzstan. Public health aspects of HIV/AIDS in low and middle income countries New York Springer 557 581
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2008 Ukraine - National report on monitoring progress towards the UNGASS declaration of commitment on HIV/AIDS. Geneva United Nations
4. KruglovYV
KobyshchaYV
SalyukT
VaretskaO
ShakarishviliA
2008 The most severe HIV epidemic in Europe: Ukraine's national HIV prevalence estimates for 2007. Sex Transm Infect 84 i37 i41
5. HamersFF
DownsAM
2003 HIV in central and eastern Europe. Lancet 361 1035 1044
6. KellyJA
AmirkhanianYA
2003 The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int J STD AIDS 14 361 371
7. DeBellD
CarterR
2005 Impact of transition on public health in Ukraine: case study of the HIV/AIDS epidemic. BMJ 331 216 219
8. SaadMD
ShcherbinskayaAM
NadaiY
KruglovYV
AntonenkoSV
2006 Molecular epidemiology of HIV Type 1 in Ukraine: birthplace of an epidemic. AIDS Res Hum Retroviruses 22 709 714
9. BarnettT
WhitesideA
KhodakevichL
KruglovY
SteshenkoV
2000 The HIV/AIDS epidemic in Ukraine: its potential social and economic impact. Soc Sci Med 51 1387 1403
10. BarcalK
SchumacherJ
DumchevK
MorozL
2005 A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine. Harm Reduct J 2 16
11. BruceRD
DvoryakS
SyllaL
AlticeFL
2007 HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. Int J Drug Policy 18 326 328
12. BoothRE
KwiatkowskiCF
BrewsterJT
SinitsynaL
DvoryakS
2006 Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS 20 2217 2223
13. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2008 Ukraine - Country situation factsheet. Geneva United Nations
14. Open Society Institute & Soros Foundation Network 2007 Newsflash Ukraine: Methadone scale up authorized. New York Open Society Institute
15. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2008 Progress towards universal access - Ukraine factsheet. Geneva United Nations
16. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance 2008 Epidemiological factsheet on HIV and AIDS: core data on epidemiology and response - Ukraine. Geneva World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS)
17. International HIV/AIDS Alliance in Ukraine 2008 International HIV/AIDS Alliance in Ukraine: 2007 annual report. Kyiv, Ukraine International HIV/AIDS Alliance in Ukraine
18. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2007 UNGASS - National Composite Policy Index (NCPI) 2007 - Ukraine. Geneva United Nations
19. SchleiferR
2006 Rhetoric and risk: human rights abuses impeding Ukraine's fight against HIV/AIDS. New York, NY Human Rights Watch
20. ConnockM
Juarez-GarciaA
JowettS
FrewE
LiuZ
2007 Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Southampton, United Kingdom National Institute for Health Research - Health Technology Assessment Programme
21. MarschLA
1998 The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 93 515 532
22. SchillingR
DornigK
LungrenL
2006 Treatment of heroin dependence: effectiveness, costs, and benefits of methadone maintenance. Res Social Work Practice 16 48 56
23. ZaricGS
BrandeauML
BarnettPG
2000 Methadone maintenance and HIV prevention: a cost-effectiveness analysis. Manage Sci 46 1013 1031
24. VickermanP
KumaranayakeL
BalakirevaO
GuinnessL
ArtyukhO
2006 The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 33 S89 S102
25. Panel on Antiretroviral Guidelines for Adults and Adolescents 2008 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda (Maryland) United States Department of Health and Human Services
26. World Health Organization (WHO) 2006 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2006 revision. Geneva World Health Organization
27. CastillaJ
del RomeroJ
HernandoV
MarincovichB
GarciaS
2005 Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J AIDS 40 96 101
28. EggerM
MayM
ChêneG
PhillipsAN
LedergerberB
2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 119 129
29. GrabarS
MoingVL
GoujardC
LeportC
KazatchkineMD
2000 Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133 401 410
30. RoyceRA
SenaA
CatesW
CohenMS
1997 Sexual transmission of HIV. N Engl J Med 336 1072 1078
31. WoodE
HoggRS
YipB
HarriganPR
O'ShaughnessyMV
2003 Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350×109 cells/L. Ann Intern Med 139 810 816
32. KaplanEH
HeimerR
1992 A model-based estimate of HIV infectivity via needle sharing. J AIDS 5 1116 1118
33. LongEF
BrandeauML
GalvinCM
VinichenkoT
ToleSP
2006 Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20 2207 2215
34. SandersGD
BayoumiAM
SundaramV
BilirSP
NeukermansCP
2005 Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352 570 585
35. International HIV/AIDS Alliance in Ukraine 2007 Report on implementing the programme supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria in Ukraine. Kyiv, Ukraine International HIV/AIDS Alliance in Ukraine
36. International HIV/AIDS Alliance in Ukraine 2008 Methadone substitution therapy starts in Ukraine. Kyiv, Ukraine International HIV/AIDS Alliance in Ukraine
37. GrönbladhL
GunneLM
1989 Methadone-assisted rehabilitation of Swedish heroin addicts. Drug Alcohol Depend 24 31 37
38. ZaricG
BarnettP
BrandeauM
2000 HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 90 1100 1111
39. BoothRE
KwiatkowskiCF
Mikulich-GilbertsonSK
BrewsterJT
Salomonsen-SautelS
2006 Predictors of risky needle use following interventions with injection drug users in Ukraine. Drug Alcohol Depend 82 S49 S55
40. BoothRE
Mikulich-GilbertsonSK
BrewsterJT
Salomonsen-SautelS
SemerikO
2004 Predictors of self-reported HIV infection among drug injectors in Ukraine. J Acquir Immune Defic Syndr 35 82 88
41. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2008 Country overview: Ukraine. Lisbon, Portugal European Monitoring Centre for Drugs and Drug Addiction
42. LiuC
OstrowD
DetelsR
HuZ
JohnsonL
2006 Impacts of HIV infection and HAART use on quality of life. Qual Life Res 15 941 949
43. GillCJ
GriffithJL
JacobsonD
SkinnerS
GorbachSL
2002 Relationship of HIV viral loads, CD4 counts, and HAART use to health-related quality of life. J AIDS 30 485 492
44. MannheimerSB
MattsJ
TelzakE
ChesneyM
ChildC
2005 Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 17 10 22
45. JelsmaJ
MacLeanE
HughesJ
TiniseX
DarderM
2005 An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care 17: 579 - 588
46. DvoriakS
2007 Opioid Substitution Therapy (OST) with buprenorphine in Ukraine - way to prevent HIV/AIDS among IDUs. In:Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22–25 July 2007; Sydney, Australia
47. World Health Organization (WHO) 2005 Summary country profile for HIV/AIDS treatment scale-up - Ukraine. Geneva World Health Organization
48. World Health Organization (WHO) 2009 Global price reporting mechanism. Geneva WHO
49. World Health Organization (WHO) 2003 Making choices in health: WHO guide to cost-effectiveness analysis. Geneva World Health Organization
50. HutubessyR
ChisholmD
EdejerTT
2003 Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1 8
51. WeinsteinMC
StasonWB
1977 Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 716 721
52. GoldM
SiegelJ
RussellL
WeinsteinM
1996 Cost-effectiveness in health and medicine. New York Oxford University Press
53. GoldMR
StevensonD
FrybackDG
2002 HALYs and QALYs and DALYs, oh my: similarities and differences in summary measures of population health. Annu Rev Public Health 23 115 134
54. MurrayCJL
SalomonJA
MathersCD
LopezAD
2002 Summary measures of population health. concepts, ethics, measurement and applications Geneva World Health Organization
55. SassiF
2006 Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 21 402 408
56. PinkertonSD
AbramsonPR
1997 Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44 1303 1312
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 3
- Jak rozpoznat pacienty s familiární hypercholesterolémií ve své praxi
- Myasthenia gravis: kombinace chirurgie a farmakoterapie jako nejefektivnější modalita?
- Statinová intolerance
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
- Mutace v genu PCSK9 zodpovědné za rozvoj familiární hypercholesterolémie
Najčítanejšie v tomto čísle
- The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices
- How Can Institutional Review Boards Best Interpret Preclinical Data?
- HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis
- Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty